140 related articles for article (PubMed ID: 35184001)
1. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.
Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
Cancer Treat Rev; 2022 Mar; 104():102357. PubMed ID: 35184001
[TBL] [Abstract][Full Text] [Related]
2. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort.
Peretti U; Cavaliere A; Niger M; Tortora G; Di Marco MC; Rodriquenz MG; Centonze F; Rapposelli IG; Giordano G; De Vita F; Stuppia L; Avallone A; Ratti M; Paratore C; Forti LG; Orsi G; Valente MM; Gaule M; Macchini M; Carrera P; Calzavara S; Simbolo M; Melisi D; De Braud F; Salvatore L; De Lorenzo S; Chiarazzo C; Falconi M; Cascinu S; Milella M; Reni M
ESMO Open; 2021 Feb; 6(1):100032. PubMed ID: 33399070
[TBL] [Abstract][Full Text] [Related]
3. Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma.
Zheng-Lin B; Rainone M; Varghese AM; Yu KH; Park W; Berger M; Mehine M; Chou J; Capanu M; Mandelker D; Stadler ZK; Birsoy O; Jairam S; Yang C; Li Y; Wong D; Benhamida JK; Ladanyi M; Zhang L; O'Reilly EM
Mol Diagn Ther; 2022 Nov; 26(6):645-653. PubMed ID: 36178671
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey.
Orsi G; Di Marco M; Cavaliere A; Niger M; Bozzarelli S; Giordano G; Noventa S; Rapposelli IG; Garajova I; Tortora G; Rodriquenz MG; Bittoni A; Penzo E; De Lorenzo S; Peretti U; Paratore C; Bernardini I; Mosconi S; Spallanzani A; Macchini M; Tamburini E; Bencardino K; Giommoni E; Scartozzi M; Forti L; Valente MM; Militello AM; Cascinu S; Milella M; Reni M
ESMO Open; 2021 Oct; 6(5):100238. PubMed ID: 34392104
[TBL] [Abstract][Full Text] [Related]
5. EUS-based Pancreatic Cancer Surveillance in
Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
[TBL] [Abstract][Full Text] [Related]
6. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
Orsi G; Cavaliere A; Tortora G; Lonardi S; Macchini M; Di Marco M; Giordano G; Vasile E; Scartozzi M; Bozzarelli S; Noventa S; Rodriquenz MG; Militello AM; Rapposelli IG; Garajova I; De Lorenzo S; Merelli B; Bittoni A; Salvatore L; Procaccio L; Paratore C; Spallanzani A; Peretti U; Niger M; Giommoni E; Bernardini I; Tamburini E; Bernardino K; Forti L; Valente MM; Cascinu S; Milella M; Reni M
Br J Cancer; 2023 Mar; 128(5):877-885. PubMed ID: 36482190
[TBL] [Abstract][Full Text] [Related]
7. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
[TBL] [Abstract][Full Text] [Related]
8. Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing.
Jiang H; Huang F; Chen X; Zhang L; Shen M; Pan B; Wang B; Guo W
Mol Genet Genomic Med; 2023 Jul; 11(7):e2170. PubMed ID: 36978154
[TBL] [Abstract][Full Text] [Related]
9. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
[TBL] [Abstract][Full Text] [Related]
10. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
11. The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants.
Laish I; Schechter M; Dancour A; Lieberman S; Levi Z; Goldberg Y; Kedar I; Hasnis E; Half E; Levi GR; Katz L; Vainer ED; Genzel D; Aharoni M; Chen-Shtoyerman R; Abu-Freha N; Raitses-Gurevich M; Golan T; Bernstein-Molho R; Ben Yehoyada M; Gluck N; Rosner G
Cancer; 2024 Jan; 130(2):256-266. PubMed ID: 37861363
[TBL] [Abstract][Full Text] [Related]
12. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
[TBL] [Abstract][Full Text] [Related]
13. BRCA-mutant pancreatic ductal adenocarcinoma.
Lai E; Ziranu P; Spanu D; Dubois M; Pretta A; Tolu S; Camera S; Liscia N; Mariani S; Persano M; Migliari M; Donisi C; Demurtas L; Pusceddu V; Puzzoni M; Scartozzi M
Br J Cancer; 2021 Nov; 125(10):1321-1332. PubMed ID: 34262146
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
[TBL] [Abstract][Full Text] [Related]
15. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
[TBL] [Abstract][Full Text] [Related]
17. Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.
Schmitt A; Feldmann G; Zander T; Reinhardt HC
Oncol Res Treat; 2018; 41(10):619-625. PubMed ID: 30286473
[TBL] [Abstract][Full Text] [Related]
18. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
Power R; Leavy C; Nolan C; White N; Clarke R; Cadoo KA; Gallagher DJ; Lowery MA
Fam Cancer; 2021 Apr; 20(2):97-101. PubMed ID: 32918181
[TBL] [Abstract][Full Text] [Related]
20. Risk of pancreatic ductal adenocarcinoma associated with carriage of BRCA1 and/or BRCA2 mutation: A systematic review and meta-analysis.
McGarry JL; Creavin B; Kelly ME; Gallagher TK
J Surg Oncol; 2022 Nov; 126(6):1028-1037. PubMed ID: 35770919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
